Ubs Asset Management Americas Inc Ventyx Biosciences, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.08 - $31.18 $58,032 - $869,922
27,900 Added 56.55%
77,234 $190,000
Q3 2023

Nov 13, 2023
BUY
$29.8 - $40.3 $921,833 - $1.25 Million
30,934 Added 168.12%
49,334 $1.71 Million
Q1 2023

May 15, 2023
BUY
$29.51 - $46.65 $91,481 - $144,615
3,100 Added 20.26%
18,400 $616,000
Q4 2022

Feb 14, 2023
BUY
$24.16 - $36.38 $369,648 - $556,614
15,300 New
15,300 $501,000

Others Institutions Holding VTYX

# of Institutions
127
Shares Held
52.9M
Call Options Held
35.3K
Put Options Held
83K
View Full List

About Ventyx Biosciences, Inc.

VTYX Quotes by TradingView
  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $116M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email